Angiotensin II Receptor Antagonists: An Emerging New Class of Cardiovascular Therapeutics.

摘要: Acceptance of the notion that physiologically specific interruption renin-angiotensin-aldosterone system (RAAS) is considerable therapeutic benefit in treatment hypertension and congestive heart failure has generated great interest search for novel pharmacological inhibitors. The RAAS expressed at whole body, organ/tissue cellular level through action octapeptide angiotensin II (Ang II), primary effector molecule RAAS. availability selective, potent, orally active long-acting nonpeptide Ang type 1 (AT1) receptor antagonists provided opportunity to obtain benefits selectively blocking AT1 mediates most, if not all, important actions II, avoid nonspecificity I converting enzyme (ACE) Losartan was first, but by no means remained only antagonist. Numerous other "sartans" have emerged past several years successfully completed clinical development. With exception Eprosartan, all others, i.e. Candesartan, Irbesartan, Saprisartan, Tasosartan, Telmisartan, Valsartan Zolasartan, are based on modifications Losartan's prototypic chemical structure. represent newest addition arsenal cardiovascular therapeutics. predominant role mediating pathophysiological underlies effectiveness this class agents lower arterial blood pressure, reduce pre- afterload, inhibit sympathetic nervous activity prevent hypertrophy cardiac induced inappropriate control (Hypertens Res 1999; 22: 147-153)